TAR-210 results show 90 percent recurrence-free survival
Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor...
Source: globenewswire.com
Rev Clin News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Rev Clin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Rev Clin Today - Breaking & Trending Today
Indirect Comparison Finds Bimekizumab More Effective Than Guselkumab in Psoriatic Arthritis
Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor necrosis factor inhibitors.
Source: ajmc.com
Enhancing Stem Cell Tracking with Nanoparticle Imaging Agents
This article from Merck discusses how in vivo stem cell tracking has recently been advanced with nanoparticle-based imaging contrast agents.
Source: azonano.com
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly or 300 mg...
Source: prnewswire.com
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly or 300 mg every other week showed higher response rates in HiSCR 50 at week 16 than those treated...
Source: lelezard.com